A group of representatives of the first generic drugs on the market have a chance

In the process of the industry's overall transformation from high sales mode to high R & D mode, the competition of generic drugs has intensified How to compete for products and markets has become the layout direction that enterprises must consider The first generic drugs have become the focus of many pharmaceutical enterprises, which has also become the opportunity for many pharmaceutical representatives Recently, Hansen pharmaceutical announced that the bismeglumine for injection developed by its subsidiary Jiangsu Hansen Pharmaceutical Co., Ltd has been approved for listing by the State Food and drug administration The drug has been declared in accordance with the new three categories of chemicals After being approved, it is deemed to have passed the consistency evaluation, and it has become the first and the only approved bismeglumine in China In fact, on September 4, the processing status of fosapitam and meglumine nmpa of Zhengda Tianqing was changed to "approved - pending approval" It is widely believed in the industry that the first generic drug used to treat chemotherapy-related vomiting is expected to successfully break through, but the game is poor after all According to the public information, 28 domestic enterprises have applied for new drugs and imitations of fosapitam In recent years, the speed of enterprises applying for the first generic drugs has been accelerating To some extent, the first generic drugs have entered a rapid harvest period: on October 14, four generic drugs "aripitan capsule" and "voltacetin hydrobromide tablets" were reported on the market At present, no domestic generic drugs of the two varieties have been approved for the market Insight According to the database, in Q1 2019, there were 10 drugs that were first imitated on the market Except that rituximab of Fuhong Hanlin was biological products, the others were chemical imitations, and all of them came from famous pharmaceutical companies: temozolomide for injection of Hengrui pharmaceutical, lamivudine tenofovir tablets of Anhui Baker biopharmaceutical, apixaban tablets and viggliptin tablets of Jiangsu Haosen pharmaceutical, Qingfeng pharmaceutical of Jiangxi The results showed that: 1 The sustained-release tablets of lakosamide, zuelacetam and trimetazidine hydrochloride of Qilu pharmaceutical According to the first approval date, there are 76 approvals for the first generic drugs from 2016 to now, among which many varieties are still exclusive imitations, and many varieties have multiple competitors Nowadays, in the process of the industry's overall transformation from high sales mode to high R & D mode, the competition of generic drugs has intensified How to seize products and market has become the layout direction that enterprises must consider, and the first copy has become the focus of many pharmaceutical enterprises In the market, the first generic drug can enter the market quickly and obtain a large quantity because it directly undertakes the original research drug and has no direct competitiveness in the early stage.